5). anti-PsaA antibodies was identified. Immunization withL. lactisMG1363 induced very low levels of IgA and IgG, possibly by the low amount of PsaA indicated in this strain and its short persistence in the nose mucosa. All three lactobacilli persisted in the nose mucosa for 3 days and produced a similar amount of PsaA protein (150250 ng per 109CFU). However,L. plantarumNCDO1193 andL. helveticusATCC15009 elicited the highest antibody response (IgA and IgG). Vaccination with recombinant lactobacilli but not with recombinantL. lactisled Trazodone HCl to a decrease inS. pneumoniaerecovery from nose mucosa upon a colonization challenge. Our results confirm that certainLactobacillusstrains have intrinsic properties that make them suitable candidates for mucosal vaccination experiments. Keywords:Lactic acid bacteria,Streptococcus pneumoniae, PsaA == 1. Intro == Streptococcus pneumoniaeis the major agent of pneumonia around the world, causing up to one million deaths per year, mainly in developing countries[1]. The high costs of medical care and the appearance of new medical isolates with multidrug resistance led to the search for Trazodone HCl efficient fresh vaccines to prevent pneumococcal infection. Since the pathogen enters the sponsor through the respiratory mucosa, a vaccine inducing the production of protecting secretory IgA at this site, as well as systemic IgG antibodies, would be desired. Pneumococcal surface antigen A (PsaA) is definitely a membrane-anchored virulence element, probably involved in Mn2+and Zn2+transport as expected by its crystal structure[2]. PsaA deletion mutants display low ability to abide by mucosal cells and therefore are less pathogenic[3]. This characteristic may be due to variations in the modulation of pneumococcal adhesins caused by the absence of Mn2+or Zn2+in the cell[4]. Trazodone HCl PsaA is definitely conserved among the 90 describedS. pneumoniaeserotypes and is also immunogenic, which makes it a good candidate for vaccine formulations. In fact, antibodies produced against PsaA by nose immunization, using cholera toxin B subunit as adjuvant, were shown to guard mice against nasopharyngeal colonization byS. pneumoniae. This safety can be further increased from the co-administration of PsaA with the pneumococcal surface protein A (PspA), another pneumococcal virulence element[5],[6]. In another approach, oral immunization of mice with PsaA encapsulated in microspheres induced the production of IgG and IgA and resulted in safety against lung colonization and septicemia with five differentS. pneumoniaestrains[7]. Live bacterial vaccine vectors are becoming extensively analyzed for mucosal immunization in the Trazodone HCl prevention of different infectious diseases[8],[9]. Among them, lactic acid bacteria (LAB) are especially attractive since they are microorganisms present in the gastrointestinal mucosa of healthy individuals, are widely used in dietary products and possess a GRAS (generally recognized as safe) status. This characteristic is not shared by attenuated pathogen derived live vectors, due to the possibility of reversion of the attenuated phenotype, which could become dangerous primarily for immunocompromised individuals. Interaction of LAB with the immune Mouse monoclonal to CD19 system and their potential as antigen service providers are the subjects of a number of recently published studies[10],[11],[12],[13],[14],[15]. Different strains and routes of inoculation were evaluated using the fragment C of the tetanus toxin (TTFC), which is so much the best characterized antigen indicated in LAB[9],[16],[17],[18]. Most of these methods resulted in safety against tetanus toxin lethal concern[16],[19]. Additional antigens like the protecting antigen fromBacillus anthracis[20], the E7 protein from human being papilloma disease 16[21], the L7/L12 antigen fromBrucella abortus[22], the Env protein from HIV[23], the M protein fromStreptococcus pyogenes[24]and the spike glycoprotein from gastroenteritis coronavirus[25]were indicated in LAB and their potential as vaccines against the connected diseases are currently being evaluated. In some cases, such as the immunization withL. lactisexpressing the HIV Env protein or the M protein fromStreptococcus pyogenes, safety was observed using adequate animal models[23],[24]. In additional instances, in vitro neutralizing effects of the antibodies were observed[25]. Using an inducible manifestation Trazodone HCl system based on the lactose operon fromLactobacillus casei[26]we indicated the PsaA and the PspA antigens fromS. pneumoniae[27]either intracellularly or secreted to the tradition press. These recombinantL. caseiare becoming tested as potential anti-pneumococcal vaccines through nose immunization of mice, but so far we could not detect significant levels of anti-PsaA IgA or IgG (unpublished data). The failure in revitalizing the production of antibodies may be a result of the lack of PsaA or PspA manifestation in the recombinantL. caseiafter nose immunization, due to the absence of the inducer in the.